Inside Biogen's scramble to sell Aduhelm: Project 'Javelin' and pressure to ID as many patients as possible
In anticipation of Aduhelm’s approval for Alzheimer’s in June, Biogen employees were directed to identify and guarantee treatment centers would administer the drug through a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
